Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
Antimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, <i>S. aureus</i> is a leading cause of mortality and morbidity. Alternative strategies to treat <i>S. aureus</i> infections, such as...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/10/2302 |
id |
doaj-01f1302fc6f5433c93db637ec3ab3193 |
---|---|
record_format |
Article |
spelling |
doaj-01f1302fc6f5433c93db637ec3ab31932020-11-25T03:12:47ZengMDPI AGMolecules1420-30492020-05-01252302230210.3390/molecules25102302Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>Beata Chudzik-Rząd0Anna Malm1Nazar Trotsko2Monika Wujec3Tomasz Plech4Agata Paneth5Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Faculty of Pharmacy, Medical University of Lublin, Chodźki 1, 20-093 Lublin, PolandDepartment of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Faculty of Pharmacy, Medical University of Lublin, Chodźki 1, 20-093 Lublin, PolandDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, PolandDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, PolandDepartment of Pharmacology, Faculty of Health Sciences, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, PolandDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, PolandAntimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, <i>S. aureus</i> is a leading cause of mortality and morbidity. Alternative strategies to treat <i>S. aureus</i> infections, such as combination therapy, are urgently needed. In this study, a checkerboard method was used to evaluate synergistic interactions between nine thiosemicarbazides (4-benzoyl-1-(2,3-dichloro-benzoyl)thiosemicarbazides <b>1</b>–<b>5</b> and 4-aryl-1-(2-fluorobenzoyl)thiosemicarbazides <b>6</b>–<b>9</b>) and conventional antibiotics against <i>S. aureus</i> ATCC 25923, which were determined as the fractional inhibitory concentration indices (FICIs). For these experiments, amoxicillin, gentamicin, levofloxacin, linezolid, and vancomycin were selected to represent the five antimicrobial classes most commonly used in clinical practice. With one exception of <b>7</b>-vancomycin combination, none of the forty-five thiosemicarbazide-antibiotic combinations tested had an antagonistic effect, showing promising results with respect to a combination therapy. The synergic effect was observed for the <b>2</b>-linezolid, <b>4</b>-levofloxacin, <b>5</b>-linezolid, <b>6</b>-gentamicin, <b>6</b>-linezolid, and <b>7</b>-levofloxacin combinations. No interactions were seen in combination of the thiosemicarbazide with gentamicin or vancomycin, whereas all combinations with linezolid acted in additive or synergism, except for <b>6</b>-gentamicin and <b>7</b>-linezolid. The 4-(4-chlorophenyl)-1-(2-fluorobenzoyl)thiosemicarbazide <b>6</b> showed a clear preference for the potency; it affected synergistically in combinations with gentamicin or linezolid and additively in combinations with amoxicillin, levofloxacin, or vancomycin. In further studies, the inhibitory potency of the thiosemicarbazides against <i>S. aureus</i> DNA gyrase and topoisomerase IV was examined to clarify the molecular mechanism involved in their synergistic effect in combination with levofloxacin. The most potent synergist <b>6</b> at concentration of 100 µM was able to inhibit ~50% activity of <i>S. aureus</i> DNA gyrase, thereby suggesting that its anti-gyrase activity, although weak, may be a possible factor contributing to its synergism effect in combination with linezolid or gentamycin.https://www.mdpi.com/1420-3049/25/10/2302thiosemicarbazidesantibacterial activitysynergistic effectbacterial topoisomerases |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Beata Chudzik-Rząd Anna Malm Nazar Trotsko Monika Wujec Tomasz Plech Agata Paneth |
spellingShingle |
Beata Chudzik-Rząd Anna Malm Nazar Trotsko Monika Wujec Tomasz Plech Agata Paneth Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i> Molecules thiosemicarbazides antibacterial activity synergistic effect bacterial topoisomerases |
author_facet |
Beata Chudzik-Rząd Anna Malm Nazar Trotsko Monika Wujec Tomasz Plech Agata Paneth |
author_sort |
Beata Chudzik-Rząd |
title |
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i> |
title_short |
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i> |
title_full |
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i> |
title_fullStr |
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i> |
title_full_unstemmed |
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i> |
title_sort |
synergistic effects of thiosemicarbazides with clinical drugs against <i>s. aureus</i> |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2020-05-01 |
description |
Antimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, <i>S. aureus</i> is a leading cause of mortality and morbidity. Alternative strategies to treat <i>S. aureus</i> infections, such as combination therapy, are urgently needed. In this study, a checkerboard method was used to evaluate synergistic interactions between nine thiosemicarbazides (4-benzoyl-1-(2,3-dichloro-benzoyl)thiosemicarbazides <b>1</b>–<b>5</b> and 4-aryl-1-(2-fluorobenzoyl)thiosemicarbazides <b>6</b>–<b>9</b>) and conventional antibiotics against <i>S. aureus</i> ATCC 25923, which were determined as the fractional inhibitory concentration indices (FICIs). For these experiments, amoxicillin, gentamicin, levofloxacin, linezolid, and vancomycin were selected to represent the five antimicrobial classes most commonly used in clinical practice. With one exception of <b>7</b>-vancomycin combination, none of the forty-five thiosemicarbazide-antibiotic combinations tested had an antagonistic effect, showing promising results with respect to a combination therapy. The synergic effect was observed for the <b>2</b>-linezolid, <b>4</b>-levofloxacin, <b>5</b>-linezolid, <b>6</b>-gentamicin, <b>6</b>-linezolid, and <b>7</b>-levofloxacin combinations. No interactions were seen in combination of the thiosemicarbazide with gentamicin or vancomycin, whereas all combinations with linezolid acted in additive or synergism, except for <b>6</b>-gentamicin and <b>7</b>-linezolid. The 4-(4-chlorophenyl)-1-(2-fluorobenzoyl)thiosemicarbazide <b>6</b> showed a clear preference for the potency; it affected synergistically in combinations with gentamicin or linezolid and additively in combinations with amoxicillin, levofloxacin, or vancomycin. In further studies, the inhibitory potency of the thiosemicarbazides against <i>S. aureus</i> DNA gyrase and topoisomerase IV was examined to clarify the molecular mechanism involved in their synergistic effect in combination with levofloxacin. The most potent synergist <b>6</b> at concentration of 100 µM was able to inhibit ~50% activity of <i>S. aureus</i> DNA gyrase, thereby suggesting that its anti-gyrase activity, although weak, may be a possible factor contributing to its synergism effect in combination with linezolid or gentamycin. |
topic |
thiosemicarbazides antibacterial activity synergistic effect bacterial topoisomerases |
url |
https://www.mdpi.com/1420-3049/25/10/2302 |
work_keys_str_mv |
AT beatachudzikrzad synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi AT annamalm synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi AT nazartrotsko synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi AT monikawujec synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi AT tomaszplech synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi AT agatapaneth synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi |
_version_ |
1724648562067767296 |